On this page
RARS2
arginyl-tRNA synthetase 2, mitochondrial
The RARS2 gene encodes a mitochondrial enzyme crucial for synthesising proteins, specifically by attaching the amino acid arginine to its transfer RNA molecule. RARS2 provides instructions for mitochondrial arginyl-tRNA synthetase, an enzyme vital for mitochondrial protein production.
RARS2 is located on the long (q) arm of chromosome 6, at band 6q15. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 6 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The RARS2 gene contains the genetic blueprint for mitochondrial arginyl-tRNA synthetase, an enzyme located within the mitochondria, often referred to as the 'powerhouses' of the cell. Mitochondria convert energy from food into a usable form for cellular processes. This gene's proper functioning is essential for synthesising proteins within these critical organelles.
What the gene does
The mitochondrial arginyl-tRNA synthetase enzyme, produced from the RARS2 gene, plays a specific role in protein synthesis. It facilitates the attachment of the amino acid arginine to its corresponding transfer RNA (tRNA) molecule. Transfer RNA molecules are crucial intermediaries in protein construction, collecting amino acids and assembling them into new proteins according to the genetic code. By linking arginine to tRNA, the RARS2 enzyme ensures that this specific amino acid can be correctly incorporated into newly formed mitochondrial proteins, which are vital for numerous cellular functions.
Video: Genetics 101
Chromosome location
The RARS2 gene is situated on the long arm of chromosome 6, at position 6q15. This gene spans a specific region of the human genome, providing the instructions for a protein that is 578 amino acids long.
Protein structure
The RARS2 protein, mitochondrial arginyl-tRNA synthetase, is composed of 578 amino acids. It includes a notable 'HIGH' region (Motif) located between amino acids 133 and 144. This motif is typically involved in the catalytic activity of aminoacyl-tRNA synthetases, highlighting its importance for the enzyme's function in attaching arginine to tRNA.
Key variants
Variations within the RARS2 gene can range from single nucleotide changes to larger deletions or insertions. Such genetic alterations may impact the function of the mitochondrial arginyl-tRNA synthetase enzyme. Pathogenic variants can lead to a reduced or absent enzyme activity, impairing mitochondrial protein synthesis and subsequently affecting cellular energy production and overall neurological development.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1141C>T | p.Gln381Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Pontocerebellar hypoplasia type 6 |
c.127C>T | p.Gln43Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Pontocerebellar hypoplasia type 6 |
c.1650+1del | - | Pathogenic/Likely pathogenic | ★★☆☆ | Pontocerebellar hypoplasia type 6 |
c.1651-2A>G | - | Pathogenic/Likely pathogenic | ★★☆☆ | Pontocerebellar hypoplasia type 6 |
c.170C>G | p.Ser57Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Pontocerebellar hypoplasia type 6 |
c.34C>T | p.Gln12Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Pontocerebellar hypoplasia type 6 |
c.3G>C | p.Met1Ile | Pathogenic/Likely pathogenic | ★★☆☆ | Pontocerebellar hypoplasia type 6 |
c.459del | p.Phe153fs | Pathogenic/Likely pathogenic | ★★☆☆ | Pontocerebellar hypoplasia type 6 |
c.721_722del | p.Trp241fs | Pathogenic/Likely pathogenic | ★★☆☆ | Pontocerebellar hypoplasia type 6 |
c.757_760dup | p.Arg254fs | Pathogenic/Likely pathogenic | ★★☆☆ | Pontocerebellar hypoplasia type 6 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the RARS2 gene are associated with inherited conditions that primarily affect the brain. These conditions often manifest as pontocerebellar hypoplasia, a disorder characterised by underdevelopment of parts of the brain, including the pons and cerebellum. Symptoms can include developmental delay, movement difficulties, and intellectual disability. Specifically, RARS2 variants are a known cause of pontocerebellar hypoplasia type 6 (PCH6).
No condition pages are linked to this gene yet. This does not mean it has no associated conditions.
UK clinical status
RARS2 is recognised within the UK's NHS Genomic Medicine Service, being featured on several Green-rated PanelApp panels. These include 'Ataxia and cerebellar anomalies - childhood onset', 'Cerebellar hypoplasia', 'Early onset or syndromic epilepsy', 'Foetal anomalies' (R21), 'Hereditary ataxia', 'Intellectual disability', 'Likely inborn error of metabolism' (R98), 'Mitochondrial disorders', 'Possible mitochondrial disorder, nuclear genes' (R63), and 'Undiagnosed metabolic disorders'. Its presence on these panels indicates its clinical significance in diagnosing relevant conditions within the UK healthcare system.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the primary function of the RARS2 gene?
The RARS2 gene provides instructions for an enzyme called mitochondrial arginyl-tRNA synthetase. This enzyme is crucial for attaching the amino acid arginine to its specific transfer RNA (tRNA) molecule, a vital step in synthesising proteins within the mitochondria.
What conditions are associated with RARS2 gene variants?
Pathogenic variants in the RARS2 gene are primarily associated with pontocerebellar hypoplasia, particularly type 6 (PCH6). This condition affects brain development, leading to developmental delay, movement problems, and intellectual disability.
How does the RARS2 gene impact health?
When the RARS2 gene has pathogenic variants, the mitochondrial arginyl-tRNA synthetase enzyme may not function correctly. This impairs the cell's ability to produce essential mitochondrial proteins, disrupting energy production and leading to various neurological and developmental issues.
References
- Cassandrini D, Cilio MR, Bianchi M. Pontocerebellar hypoplasia type 6 caused by mutations in RARS2: definition of the clinical spectrum and molecular findings in five patients. Journal of inherited metabolic disease. 2013. PMID: 22569581
- Glamuzina E, Brown R, Hogarth K. Further delineation of pontocerebellar hypoplasia type 6 due to mutations in the gene encoding mitochondrial arginyl-tRNA synthetase, RARS2. Journal of inherited metabolic disease. 2012. PMID: 22086604
- Namavar Y, Barth PG, Kasher PR. Clinical, neuroradiological and genetic findings in pontocerebellar hypoplasia. Brain : a journal of neurology. 2011. PMID: 20952379
- Edvardson S, Shaag A, Kolesnikova O. Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. American journal of human genetics. 2007. PMID: 17847012